24/02/2017 11:10:41

NeuroSearch A/S releasing Annual Report 2016

Related content
05 Dec - 
Update on NeuroSearch’s business status and future
17 Nov - 
NeuroSearch upgrades its guidance for 2017
31 Aug - 
NeuroSearch A/S – H1 report 2017
Related debate
14 Feb - 
Det var du heldig så
14 Feb - 
Ville have købt for 4,6 mio. kr. men kan ikke la..
14 Feb - 
Den handles ikke i vinterferien (alle aktionærern..

Company announcement

24 February 2017

The full version of the Annual Report 2016 for NeuroSearch is available in the enclosed PDF file.

In 2016, the NeuroSearch Group (NEUR) posted an operating loss on continuing operations of DKK 6 million (2015: 7 million), which was on a level with the Company's previously announced expectations of an operating loss of DKK 4-6 million.

The Company posted a profit of DKK 1 million on discontinued operations (2015: DKK 1 million).

NeuroSearch posted an income after tax on continuing operations of DKK 22 million (2015: loss of DKK 7 million). The income for the year includes recycling of currency translation in the amount of DKK 23.5 million.

Consolidated profit was an income of DKK 23 million (2015: loss of DKK 6 million).

At the end of 2016, cash and cash equivalents totalled DKK 74 million (2015: DKK 78 million).

For a complete description of performance in the 2016 financial year, we refer to the Annual Report 2016 of NeuroSearch accompanying this announcement, and which is also available on our website as from today.

Outlook for 2017

In 2017, NeuroSearch expects an operating loss in the range of DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any income from the possible sale of Company assets, other potential income from the Company's agreements with Teva, Saniona or others.

Karin Garre                                                                       Allan Andersen

Chairman                                                                          CEO

Contact

Allan Andersen, CEO, mobile +45 4016 3864.

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.

 

APPENDIX

Financial highlights for the NeuroSearch Group

 

(DKK millions)

 

2012

2013

2014

2015

2016

 

 

 

Income statement and comprehensive income

 

 

 

 

 

 

Gain from divestment of intellectual property

 

120.7

28.8

-

-

1.3

Development costs

 

457.2

21.7

-

-

-

General and administrative costs

 

(46.7)

16.7

13.3

6.5

7.6

Operating profit/(loss)

 

(289.8)

(9.6)

(13.3)

(6.5)

(6.3)

Net financials

 

(37.2)

5.1

2.7

(0.3)

27.9

Profit/(loss) of continuing operations before tax

 

(327.1)

(4.5)

(10.6)

(6.8)

21.6

Net profit/(loss) of discontinued operations

 

57.4

15.6

1.6

1.3

1.2

Profit/(loss) for the period

 

(275.6)

12.4

(7.7)

(5.5)

22.8

Comprehensive income**

 

(243.5)

6.6

(10.2)

(5.3)

(1.0)

 

 

 

 

 

 

Balance sheet

 

 

 

 

 

 

Total assets

 

207.5

92.2

84.0

78.6

79.4

Cash and cash equivalents and securities

 

81.4

88.8

83.4

78.0

74.4

Equity

 

81.1

88.0

77.7

72.4

71.4

 

 

 

 

 

 

 

Investments

 

 

 

 

 

 

Per share ratios* (DKK)

 

 

 

 

 

 

Earnings per share

 

(11.22)

0.50

(0.32)

(0.23)

0.93

Diluted earnings per share

 

(11.22)

0.50

(0.32)

(0.23)

0.93

Net asset value

 

3.30

3.58

3.17

2.95

2.91

Market price at year-end

 

3.74

3.10

2.59

2.51

3.01

Market price/net asset value

 

1.13

0.87

0.82

0.85

1.04

 

 

 

 

 

 

 

Average number of employees

 

88

18

2

2

2

Number of employees at 31 December

 

26

2

2

2

2

*     The ratios are stated in accordance with "Recommendations and Financial Ratios" issued by The Danish Finance Society.

**    Comprehensive income includes unrealised currency translation adjustment and fair value adjustment of the hedge of the net investment in NeuroSearch Sweden AB.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Feb
NEUR
Den handles ikke i vinterferien (alle aktionærerne er på skiferie med deres forældre)
1

Elliott Capital Advisors, L.P : Form 8.3 - MELROSE INDUSTRIES PLC

16/02/2018 15:25:32
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners an..

Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers

16/02/2018 13:00:19
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management   SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of cu..

Boussard & Gavaudan Investment Management LLP : Form 8.3 - UBM plc

16/02/2018 10:19:24
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Manage..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PHOTO RELEASE--Huntington Ingalls Industries Awarded $1.43 Billion Contract For The Construction of LPD 29
2
Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
3
QUANTUM CORPORATION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Quantum Corporation - QTM
4
WELLS FARGO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Wells Fargo & Company - WFC
5
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN)

Related stock quotes

NeuroSearch A/S 4.93 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 February 2018 19:06:43
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180209.1 - EUROWEB4 - 2018-02-17 20:06:43 - 2018-02-17 19:06:43 - 1000 - Website: OKAY